CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma
1. GD2-CART01 infusion had an overall response of 63% of patients (33% complete response) with a 3-year overall survival of ...
1. GD2-CART01 infusion had an overall response of 63% of patients (33% complete response) with a 3-year overall survival of ...
1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 ...
1. Patients with B-cell non-Hodgkin's lymphoma receiving tisagenlecleucel did not show delayed lymphoma progression compared to those receiving standard salvage ...
1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene ciloleucel (axi-cel) showed improvement in event-free survival compared ...
1. Idecabtagene vicleucel treatment showed substantial antitumor activity in the majority of pre-treated patients with refractory and relapsed myeloma. 2. ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.